Skip to main content
Top
Published in: BMC Cancer 1/2018

Open Access 01-12-2018 | Research article

Survival after the diagnosis of breast or colorectal cancer in the GAZA Strip from 2005 to 2014

Authors: Chiara Panato, Khaled Abusamaan, Ettore Bidoli, Mokhtar Hamdi-Cherif, Daniela Pierannunzio, Stefano Ferretti, Mahmoud Daher, Fouad Elissawi, Diego Serraino

Published in: BMC Cancer | Issue 1/2018

Login to get access

Abstract

Background

Within a dramatic socio-political context, cancer represents a growing health burden in the Gaza Strip. We investigated the survival experience of people diagnosed with breast (BC) or colorectal (CRC) cancer from 2005 to 2014.

Methods

Data included 1360 BC cases (median age 55.1 years) and 722 CRC cases (median age: 59.5 years; 52.5% men) recorded by the Gaza Cancer Registry according to a standard protocol. Clinical information was available for cases diagnosed in 2005–2006 only. Survival probabilities were estimated by Kaplan-Meyer method, while hazard ratios (HRs) and 95% confidence intervals (CI), adjusted for age and sex, were computed to assess factors associated with the risk of death.

Results

Five-year survival was 65.1% for women with BC and 50.2% for patients with CRC. Advanced age (> 65 years), stage, and grade increased the death risk. Full access to therapies was associated with a reduced risk of death as compared with patients who had limited access (HR = 0.26, 95% CI:0.13–0.51 for BC; and HR = 0.11, 95% CI:0.04–0.31 for CRC).

Conclusion(s)

The 5-year survival after BC or CRC in the Gaza Strip was in line with estimates from surrounding Arab countries, but it was much lower than in developed Mediterranean countries (e.g., in Italy or in Jewish people in Israel).
Literature
2.
go back to reference Giacaman R, Khatib R, Shabaneh L, Ramlawi A, Sabri B, Sabatinelli G, et al. Health status and health services in the occupied Palestinian territory. Lancet. 2009;373:837–49.CrossRef Giacaman R, Khatib R, Shabaneh L, Ramlawi A, Sabri B, Sabatinelli G, et al. Health status and health services in the occupied Palestinian territory. Lancet. 2009;373:837–49.CrossRef
5.
go back to reference Husseini A, Abu-Rmeileh NM, Mikki N, Ramahi TM, Ghosh HA, Barghuthi N, et al. Cardiovascular diseases, diabetes mellitus, and cancer in the occupied Palestinian territory. Lancet. 2009;373:1041–9.CrossRefPubMed Husseini A, Abu-Rmeileh NM, Mikki N, Ramahi TM, Ghosh HA, Barghuthi N, et al. Cardiovascular diseases, diabetes mellitus, and cancer in the occupied Palestinian territory. Lancet. 2009;373:1041–9.CrossRefPubMed
9.
go back to reference Giordano L, Bisanti L, Salamina G, Ancelle Park R, Sancho-Garnier H, Espinas J, et al. The EUROMED CANCER network: state-of-art of cancer screening programmes in non-EU Mediterranean countries. Eur J Pub Health. 2016;26:839.CrossRef Giordano L, Bisanti L, Salamina G, Ancelle Park R, Sancho-Garnier H, Espinas J, et al. The EUROMED CANCER network: state-of-art of cancer screening programmes in non-EU Mediterranean countries. Eur J Pub Health. 2016;26:839.CrossRef
11.
go back to reference Armitage P, Berry G, Matthews JNS. Statistical methods in medical research. 4th ed. Malden: Blackwell Science; 2002.CrossRef Armitage P, Berry G, Matthews JNS. Statistical methods in medical research. 4th ed. Malden: Blackwell Science; 2002.CrossRef
12.
go back to reference Kalbfleish J, Prentice R. The statistical analyses of failure time data. 2nd ed. New York: Wiley; 2002.CrossRef Kalbfleish J, Prentice R. The statistical analyses of failure time data. 2nd ed. New York: Wiley; 2002.CrossRef
13.
go back to reference Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, et al. GLOBOCAN 2012 v1.0, Cancer incidence and mortality worldwide: IARC CancerBase no. 11. Lyon, France: International Agency for Research on. Cancer. 2013; Available at: http://globocan.iarc.fr Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, et al. GLOBOCAN 2012 v1.0, Cancer incidence and mortality worldwide: IARC CancerBase no. 11. Lyon, France: International Agency for Research on. Cancer. 2013; Available at: http://​globocan.​iarc.​fr
14.
go back to reference Arkoob K, Al-Nsour M, Al-Nemry O, Al-Hajawi B. Epidemiology of breast cancer in women in Jordan: patient characteristics and survival analysis. East Mediterr Health J. 2010;16:1032–8.CrossRefPubMed Arkoob K, Al-Nsour M, Al-Nemry O, Al-Hajawi B. Epidemiology of breast cancer in women in Jordan: patient characteristics and survival analysis. East Mediterr Health J. 2010;16:1032–8.CrossRefPubMed
15.
go back to reference Seedhom AE, Kamal NN. Factors affecting survival of women diagnosed with breast Cancer in El-Minia governorate. Egypt Int J Prev Med. 2011;2:131–8.PubMed Seedhom AE, Kamal NN. Factors affecting survival of women diagnosed with breast Cancer in El-Minia governorate. Egypt Int J Prev Med. 2011;2:131–8.PubMed
17.
go back to reference Smirnov M, Lazarev I, Perry ZH, Ariad S, Kirshtein B. Colorectal cancer in southern Israel: comparison between Bedouin Arab and Jewish patients. Int J Surg. 2016;33(Part A):109–16.CrossRefPubMed Smirnov M, Lazarev I, Perry ZH, Ariad S, Kirshtein B. Colorectal cancer in southern Israel: comparison between Bedouin Arab and Jewish patients. Int J Surg. 2016;33(Part A):109–16.CrossRefPubMed
18.
go back to reference Allemani C, Sant M, Weir K, Richardson LC, Baili P, Storm H, et al. Breast cancer survival in the US and Europe: a CONCORD high-resolution study. Int J Cancer. 2013;132:1170–81.CrossRefPubMed Allemani C, Sant M, Weir K, Richardson LC, Baili P, Storm H, et al. Breast cancer survival in the US and Europe: a CONCORD high-resolution study. Int J Cancer. 2013;132:1170–81.CrossRefPubMed
19.
go back to reference Minicozzi P, Kaleci S, Maffei S, Allemani C, Giacomin A, Caldarella A, et al. Disease presentation, treatment and survival for colorectal cancer patients: a EUROCARE high-resolution study. Eur J Pub Health. 2013;24:98–100.CrossRef Minicozzi P, Kaleci S, Maffei S, Allemani C, Giacomin A, Caldarella A, et al. Disease presentation, treatment and survival for colorectal cancer patients: a EUROCARE high-resolution study. Eur J Pub Health. 2013;24:98–100.CrossRef
20.
go back to reference Coleman MP, Quaresma M, Berrino F, Lutz JM, De Angelis R, Capocaccia R, et al. Cancer survival in five continents: a worldwide population-based study (CONCORD). Lancet Oncol. 2008;9:730–56.CrossRefPubMed Coleman MP, Quaresma M, Berrino F, Lutz JM, De Angelis R, Capocaccia R, et al. Cancer survival in five continents: a worldwide population-based study (CONCORD). Lancet Oncol. 2008;9:730–56.CrossRefPubMed
21.
go back to reference Sankaranarayanan R, Swaminathan R, Brenner H, Chen K, Chia KS, Chen JG, et al. Cancer survival in Africa, Asia, and central America: a population-based study. Lancet Oncol. 2010;11:165–73.CrossRefPubMed Sankaranarayanan R, Swaminathan R, Brenner H, Chen K, Chia KS, Chen JG, et al. Cancer survival in Africa, Asia, and central America: a population-based study. Lancet Oncol. 2010;11:165–73.CrossRefPubMed
23.
go back to reference Lakkis NA, Adib SM, Osman MH, Musharafieh UM, Hamadeh GN. Breast cancer in Lebanon: incidence and comparison to regional and western countries. Cancer Epidemiol. 2010;34:221–5.CrossRefPubMed Lakkis NA, Adib SM, Osman MH, Musharafieh UM, Hamadeh GN. Breast cancer in Lebanon: incidence and comparison to regional and western countries. Cancer Epidemiol. 2010;34:221–5.CrossRefPubMed
Metadata
Title
Survival after the diagnosis of breast or colorectal cancer in the GAZA Strip from 2005 to 2014
Authors
Chiara Panato
Khaled Abusamaan
Ettore Bidoli
Mokhtar Hamdi-Cherif
Daniela Pierannunzio
Stefano Ferretti
Mahmoud Daher
Fouad Elissawi
Diego Serraino
Publication date
01-12-2018
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2018
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-018-4552-x

Other articles of this Issue 1/2018

BMC Cancer 1/2018 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine